Amgen (XSGO:AMGN) EV-to-EBIT : 29.30 (As of May. 14, 2024)

View and export this data going back to . Start your Free Trial

What is Amgen EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Amgen's Enterprise Value is $219,775 Mil. Amgen's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was $7,501 Mil. Therefore, Amgen's EV-to-EBIT for today is 29.30.

The historical rank and industry rank for Amgen's EV-to-EBIT or its related term are showing as below:

XSGO:AMGN' s EV-to-EBIT Range Over the Past 10 Years
Min: 9.92 Med: 15.01 Max: 29.48
Current: 29.3

During the past 13 years, the highest EV-to-EBIT of Amgen was 29.48. The lowest was 9.92. And the median was 15.01.

XSGO:AMGN's EV-to-EBIT is ranked worse than
71.41% of 668 companies
in the Drug Manufacturers industry
Industry Median: 17.92 vs XSGO:AMGN: 29.30

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Amgen's Enterprise Value for the quarter that ended in Mar. 2024 was $191,057 Mil. Amgen's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was $7,501 Mil. Amgen's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 3.93%.

Amgen EV-to-EBIT Historical Data

The historical data trend for Amgen's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amgen EV-to-EBIT Chart

Amgen Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-EBIT

Get a 7-Day Free Trial

15.69

16.53

19.10

19.41

19.37

Amgen Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EV-to-EBIT	Get a 7-Day Free Trial															14.79	12.95	15.11	19.37	27.57

Competitive Comparison of Amgen's EV-to-EBIT

For the Drug Manufacturers - General subindustry, Amgen's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Amgen's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Amgen's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Amgen's EV-to-EBIT falls into.

Amgen EV-to-EBIT Calculation

Amgen's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	219775.281	/	7501
	=	29.30

Amgen's current Enterprise Value is $219,775 Mil.
Amgen's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $7,501 Mil.

Amgen (XSGO:AMGN) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Amgen's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2024 )	=	EBIT	/	Enterprise Value (Q: Mar. 2024 )
	=	7501	/	191057.09204
	=	3.93 %

Amgen's Enterprise Value for the quarter that ended in Mar. 2024 was $191,057 Mil.
Amgen's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $7,501 Mil.

Amgen EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Amgen's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Amgen (XSGO:AMGN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amgen Inc (XSGO:AMGN) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

AMGN:USA AMG N:Mexico AMGd:UK 0R0T:UK AMG:Germany AMG:Germany AMG:Germany AMG:Germany AMGN34:Brazil AMGN:Austria AMGN:Argentina

Address

One Amgen Center Drive, Thousand Oaks, CA, USA, 91320-1799

Website

https://www.amgen.com

Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.